Patheon, a subsidiary of Thermo Fisher Scientific, operates within the manufacturing sector, specifically focusing on the biotechnology and pharmaceutical industries. Established in 2014 and based in the United States, the company employs between 5,001 and 10,000 individuals and has reported significant revenue. Patheon specializes in drug development services, emphasizing the optimization of preclinical pathways to facilitate faster transitions to First-in-Human trials. Their documented approach includes integrated solutions that streamline processes, reduce risks, and enhance efficiency in drug development. They address challenges such as regulatory complexities and study design inefficiencies, which can delay clinical milestones. Additionally, Patheon provides guidance on clinical trial packaging and strategies to accelerate the development of complex molecules through improved chemical synthesis and formulation. Their resources highlight the importance of collaboration and communication in navigating the complexities of drug development, ultimately aiming to support biotech companies in delivering innovative therapies to market more effectively.